CagriSema
Also known as: Cagrilintide + Semaglutide · CagriSema combo
A fixed-combination metabolic agent that pairs the amylin analog cagrilintide with the GLP-1 agonist semaglutide to act on appetite and satiety through two complementary pathways.
Class
Amylin analog + GLP-1 agonist combination
Default unit
mg
Common route
Subcutaneous
Typical half-life
Long-acting (both components ~7 days)
Frequency
Once weekly
Commonly associated areas
Illustrative map of the body systems CagriSema is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.
Proposed mechanisms / pathways
What is CagriSema?
CagriSema is a fixed-dose combination of two peptides: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. The idea behind pairing them is that amylin and GLP-1 signaling influence appetite through different but complementary routes, so the combination is studied as a single weekly metabolic agent rather than as two separate tools. Both components are long-acting, which is why it is associated with once-weekly dosing.
How it is thought to work
The two components are thought to act on appetite and satiety in parallel. The GLP-1 side is reported to support insulin release when blood sugar is high, slow gastric emptying, and reduce hunger signaling in the brain, while the amylin side is thought to promote a sense of fullness and help regulate food intake. Combining them is studied on the premise that two satiety pathways together may have a more pronounced effect on appetite than either alone — though individual responses vary and the science is still evolving.
Educational only — not medical advice
CagriSema is an investigational combination still under clinical study and is not a general-use product. Nothing here is a recommendation, dose, or medical claim — speak with a qualified healthcare provider about any metabolic protocol.
Tracking CagriSema in LynkDose
A combination like CagriSema is typically titrated over weeks, so record-keeping is where LynkDose helps most. Log each weekly dose with its date, mark when the dose steps up, do a consistent weekly weigh-in, and note appetite and any side effects. With that history in one place, a plateau or a change in tolerance becomes something you can see and discuss rather than guess at.
Commonly discussed for
- Appetite and craving regulation
- Weight-management protocols under medical supervision
- Combined GLP-1 and amylin approaches
Often stacked: CagriSema is itself a combination of cagrilintide and semaglutide, so it is generally used as a single agent rather than stacked further.
How to track CagriSema in LynkDose
Because CagriSema is a weekly, titrated combination, logging the date of every dose step alongside a consistent weekly weigh-in lets you connect changes in appetite, weight, and side effects to a specific stage of the protocol.
Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)
Not medical advice
This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.